Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Lactobacillus brevis has been investigated for its potential to reduce side effects associated with chemotherapy, particularly gastrointestinal disturbances such as diarrhea and mucositis. The interest in probiotics, including L. brevis, stems from their ability to modulate the gut microbiota, enhance mucosal barrier function, and influence immune responses, all of which are often disrupted during chemotherapy. Several preclinical studies in animal models have shown that L. brevis can reduce the severity of chemotherapy-induced mucositis and maintain the integrity of the gut lining. For example, some studies demonstrated that administration of L. brevis CD2 reduced inflammation and mucosal injury in the oral cavity and intestines.

In humans, the evidence remains limited but promising. Small-scale clinical trials and case reports suggest that L. brevis (often in the form of lozenges or probiotic mixtures) may help prevent or reduce oral mucositis in patients undergoing chemotherapy or radiotherapy, particularly for head and neck cancers. However, these studies are often limited by small sample sizes, lack of controls, or use of multi-strain probiotic formulations, making it difficult to attribute effects specifically to L. brevis. Major oncology guidelines still consider the evidence insufficient for routine recommendation, but ongoing research continues to clarify its role.

In summary, there is emerging scientific support for the use of Lactobacillus brevis in mitigating chemotherapy-related side effects, but the clinical evidence is not yet robust or conclusive.

More about lactobacillus brevis
More about Chemotherapy (reducing side effects)

Other ingredients used for Chemotherapy (reducing side effects)

Other health conditions supported by lactobacillus brevis

Products containing lactobacillus brevis

Douglas Laboratories Multi-Probiotic ® 40 Billion
Douglas Laboratories Multi-Probiotic ® 40 Billion